Literature DB >> 20826579

Abrogation of TLR4 and CD14 expression and signaling in human adrenocortical tumors.

Waldemar Kanczkowski1, Piotr Tymoszuk, Monika Ehrhart-Bornstein, Manfred P Wirth, Kai Zacharowski, Stefan R Bornstein.   

Abstract

CONTEXT: Adrenocortical carcinoma (ACC) is a rare tumor with poor prognosis. The expression of innate immunity receptor Toll-like receptor 4 (TLR4) was recently reported in various human tumors, and TLR4 was shown to regulate tumor immune escape processes, proliferation, and resistance to chemotherapeutical agents.
OBJECTIVE: The aim of this study was to investigate TLR4 expression, signaling, and function in the process of tumorigenesis in the human adrenal cortex.
MEASUREMENTS AND MAIN RESULTS: Real-time PCR analysis of human ACC (n=8), adenoma (n=8), and ACC cell lines (SW13, NCI-H295R, and HAC15) revealed a significant down-regulation of TLR4, MD2 (myeloid differentiation protein-2), and cluster of differentiation 14 (CD14) mRNA compared with normal human adrenal cortex and adrenocortical cells in primary culture. Furthermore, immunohistochemistry revealed an abrogation of TLR4 and CD14 expression in ACC but not adenoma tissues. Western blot analysis of MAPK, AKT, activator protein-1, and nuclear factor-κB signaling revealed that the ACC cell lines are unresponsive to lipopolysaccharide action. Restoration of TLR4 signaling by stable transfection of TLR4-CD14 plasmid into NCI-H295R cells sensitized them to lipopolysaccharide incubation as shown by nuclear factor-κB activation and decreased cell viability and induced apoptosis in these cells.
CONCLUSION: Our results demonstrate a significant reduction in the expression of TLR4 and CD14 and an inactivation of TLR4 signaling in ACCs. Furthermore, our data show that reintroduction of TLR4 expression in ACCs may provide a novel therapeutic strategy for adrenal cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20826579     DOI: 10.1210/jc.2010-1100

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis.

Authors:  Alexia Belavgeni; Stefan R Bornstein; Anne von Mässenhausen; Wulf Tonnus; Julian Stumpf; Claudia Meyer; Evelyn Othmar; Markus Latk; Waldemar Kanczkowski; Matthias Kroiss; Constanze Hantel; Christian Hugo; Martin Fassnacht; Christian G Ziegler; Andrew V Schally; Nils P Krone; Andreas Linkermann
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

2.  Antitumoral effects of 9-cis retinoic acid in adrenocortical cancer.

Authors:  Diana Rita Szabó; Kornélia Baghy; Peter M Szabó; Adrienn Zsippai; István Marczell; Zoltán Nagy; Vivien Varga; Katalin Éder; Sára Tóth; Edit I Buzás; András Falus; Ilona Kovalszky; Attila Patócs; Károly Rácz; Peter Igaz
Journal:  Cell Mol Life Sci       Date:  2013-06-27       Impact factor: 9.261

3.  Construction of a risk signature for adrenocortical carcinoma using immune-related genes.

Authors:  Yang Fu; Shanshan Sun; Jianbin Bi; Chuize Kong
Journal:  Transl Androl Urol       Date:  2020-10

4.  The various faces of autoimmune endocrinopathies: non-tumoral hypergastrinemia in a patient with lymphocytic colitis and chronic autoimmune gastritis.

Authors:  Eugen Melcescu; Reed B Hogan; Keith Brown; Stewart A Boyd; Thomas L Abell; Christian A Koch
Journal:  Exp Mol Pathol       Date:  2012-10-05       Impact factor: 3.362

Review 5.  Toll-like receptor 4 activation in cancer progression and therapy.

Authors:  Alja Oblak; Roman Jerala
Journal:  Clin Dev Immunol       Date:  2011-11-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.